• AI
  • Molecular Imaging
  • CT
  • X-Ray
  • Ultrasound
  • MRI
  • Facility Management
  • Mammography

Can a New Prostate MRI Software Have an Impact?

News
Article

Emphasizing restriction spectrum imaging (RSI), the recently launched prostate MRI software OnQ Prostate may enhance PI-RADS assessments and workflow efficiency.

In order to enhance the detection of clinically significant prostate cancer (csPCa), Cortechs.ai has launched OnQ Prostate, a post-processing software that may bolster prostate MRI interpretation through a proprietary diffusion-weighted imaging called restriction spectrum imaging (RSI).

Originally developed for brain cancer imaging, RSI reportedly increases the detection of aggressive cancer cells, according to Cortechs.ai. The company noted that research with the FDA-cleared OnQ Prostate software has demonstrated improved in vivo characterization and localization of csPCa on diffusion MRI imaging.

Can a New Prostate MRI Software Have an Impact?

The FDA-cleared OnQ Prostate software has demonstrated improved in vivo characterization and localization of csPCa on diffusion MRI imaging, according to Cortechs.ai, the developer of the software. (Image courtesy of Cortechs.ai .)

In addition to improved accuracy with PI-RADS assessments, Cortechs.ai said the OnQ Prostate software offers a versatility that can enhance workflows with radiologists and referring providers by facilitating patient selection for biopsy procedures, treatment planning and post-treatment assessment.

“This announcement is an important step in increasing the awareness and accessibility of OnQ Prostate beyond its earliest adopters so that more physicians and patients can benefit from this technology,” says Brittany Hunt, the head of prostate business development at Cortechs.ai.

Related Videos
Emerging Research at SNMMI Examines 18F-flotufolastat in Managing Primary and Recurrent Prostate Cancer
Could Pluvicto Have a Role in Taxane-Naïve mCRPC?: An Interview with Oliver Sartor, MD
Where the USPSTF Breast Cancer Screening Recommendations Fall Short: An Interview with Stacy Smith-Foley, MD
A Closer Look at MRI-Guided Transurethral Ultrasound Ablation for Intermediate Risk Prostate Cancer
Improving the Quality of Breast MRI Acquisition and Processing
Can Fiber Optic RealShape (FORS) Technology Provide a Viable Alternative to X-Rays for Aortic Procedures?
Can Diffusion Microstructural Imaging Provide Insights into Long Covid Beyond Conventional MRI?
Emerging MRI and PET Research Reveals Link Between Visceral Abdominal Fat and Early Signs of Alzheimer’s Disease
Nina Kottler, MD, MS
The Executive Order on AI: Promising Development for Radiology or ‘HIPAA for AI’?
Related Content
© 2024 MJH Life Sciences

All rights reserved.